Clinical Trial Update: Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19. [Phase 4]

View source ↗

Summary

A phase 4 clinical trial evaluating a mineralocorticoid receptor antagonist for COVID-19 pneumonia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Snippet

Sponsor: Pomeranian Medical University Szczecin | Conditions: COVID-19 Pneumonia | Phase 4 | Status: UNKNOWN